**Test Report Status** 

**Preliminary** 



**Biological Reference Interval** Units

PATIENT NAME: KUNAL PATHAK 291495	REF. DOCTOR : S	SELF
CODE/NAME & ADDRESS : C000138375	ACCESSION NO : 0061XC000682	AGE/SEX : 36 Years Male
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL	PATIENT ID : KUNAM09038861	DRAWN :
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	CLIENT PATIENT ID:	RECEIVED : 09/03/2024 10:09:29
NEW DELHI 110030	ABHA NO :	REPORTED :09/03/2024 19:37:16
8800465156		
		<u> </u>

Results

HAEMATOLOGY - CBC			
MEDI WHEEL FULL BODY HEALTH CHECK UP BI	ELOW 40 MALE		,
BLOOD COUNTS, EDTA WHOLE BLOOD			
HEMOGLOBIN (HB)	14.2	13.0 - 17.0	g/dL
RED BLOOD CELL (RBC) COUNT	5.38	4.5 - 5.5	mil/µL
WHITE BLOOD CELL (WBC) COUNT	7.28	4.0 - 10.0	thou/µL
PLATELET COUNT	282	150 - 410	thou/µL
RBC AND PLATELET INDICES			
HEMATOCRIT (PCV)	43.5	40 - 50	%
MEAN CORPUSCULAR VOLUME (MCV)	80.9 Low	83 - 101	fL
MEAN CORPUSCULAR HEMOGLOBIN (MCH)	26.4 Low	27.0 - 32.0	pg
MEAN CORPUSCULAR HEMOGLOBIN	32.6	31.5 - 34.5	g/dL
	12.0	11.6 - 14.0	%
RED CELL DISTRIBUTION WIDTH (RDW)	13.8 <b>11.9 High</b>		% fL
MEAN PLATELET VOLUME (MPV)	11.9 High	6.8 - 10.9	IL
WBC DIFFERENTIAL COUNT			
NEUTROPHILS	52	40 - 80	%
LYMPHOCYTES	44 High	20 - 40	%
MONOCYTES	02	20 - 40 2 - 10	%
EOSINOPHILS	02	1 - 6	%
BASOPHILS	00	< 1 - 2	% %
DAJUFHILJ	00	< 1 - 2	70

<b>Interpretation(s)</b> BLOOD COUNTS,EDTA WHOLE BLOOD-The cell morphology is well preserved for 24hrs. However after 24-48 hrs a progressive increase in MCV and HCT is observed leading to a decrease in MCHC. A direct smear is recommended for an accurate differential count and for examination of RBC morphology. RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13) from Beta thalassaemia trait

Itisha.

Dr. Itisha Dhiman Pathologist



Dr. Tarun Sharma **Consultant Pathologist** 



Page 1 Of 15

View Details





PATIENT NAME: KUNAL PATHAK 291495	REF. DOCTOR :	SELF
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	ACCESSION NO: <b>0061XC000682</b> PATIENT ID : KUNAM09038861 CLIENT PATIENT ID: ABHA NO :	AGE/SEX :36 Years Male DRAWN : RECEIVED :09/03/2024 10:09:29 REPORTED :09/03/2024 19:37:16
Test Report Status Preliminary	Results Biological	Reference Interval Units

(<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for

diagnosing a case of beta thalassaemia trait. WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR < 3.3, COVID-19 patients tend to show mild disease. (Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients A.-P. Yang, et al. International Immunopharmacology 84 (2020)

106504

This ratio element is a calculated parameter and out of NABL scope.

Dr. Itisha Dhiman Pathologist



Dr. Tarun Sharma **Consultant Pathologist** 





Page 2 Of 15

View Details





**PERFORMED AT :** Agilus Diagnostics Ltd.



PATIENT NAME: KUNAL PATHAK 291495	<b>REF. DOCTOR :</b> S	ELF
CODE/NAME & ADDRESS : C000138375	ACCESSION NO : 0061XC000682	AGE/SEX : 36 Years Male
	PATIENT ID :KUNAM09038861	DRAWN :
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	CLIENT PATIENT ID:	RECEIVED : 09/03/2024 10:09:29
	ABHA NO :	REPORTED :09/03/2024 19:37:16
8800465156		

Test Report Status	<u>Preliminary</u>	Results	<b>Biological Reference Interval</b>	Units

	HAEMATOLOGY			
MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE				
ERYTHROCYTE SEDIMENTATION RATE (ESI BLOOD	R),EDTA			
E.S.R METHOD : WESTERGREN METHOD	15 High	0 - 14	mm at 1 hr	
GLYCOSYLATED HEMOGLOBIN(HBA1C), ED	TA WHOLE			
BLOOD				
HBA1C	6.3 High	Non-diabetic: < 5.7 Pre-diabetics: 5.7 - 6.4 Diabetics: > or = 6.5 ADA Target: 7.0 Action suggested: > 8.0	%	
ESTIMATED AVERAGE GLUCOSE(EAG)	134.1 High	< 116.0	mg/dL	

<b>Interpretation(s)</b>

ERYTHROCYTE SEDIMENTATION RATE (ESR), EDTA BLOOD-<b>TEST DESCRIPTION</b> :-

Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition.CRP is superior to ESR because it is more sensitive and reflects a more rapid change. <br/><b>TEST INTERPRETATION</b>

<b>Increase</b> in: Infections, Vasculities, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy, Estrogen medication, Aging.

(Paraproteiner), Estogen metadoli, yang. Finding a very accelerated ESR<b>(>100 mm/hour)</b> in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias, Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis). In pregnancy BRI in first trimester is 0-48 mm/hr(62 if anemic) and in second trimester (0-70 mm /hr(95 if anemic). ESR returns to normal 4th week post partum. <b>Decreased</b> in: Polycythermia vera, Sickle cell anemia

<b>LIMITATIONS</b>

<b>False elevated</b> ESR : Increased fibrinogen, Drugs(Vitamin A, Dextran etc), Hypercholesterolemia <b>False Decreased</b> : Poikilocytosis,(SickleCells,spherocytes),Microcytosis, Low fibrinogen, Very high WBC counts, Drugs(Quinine,

salicylates)

**REFERENCE** :

1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin 3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis,10th edition.

gtisha.

Dr. Tarun Sharma

**Consultant Pathologist** 

Dr. Itisha Dhiman Pathologist





Page 3 Of 15

View Details

View Report 

000006738420

PERFORMED AT :
Agilus Diagnostics Ltd.
M/S S.S. Wellness Centre, Ground Floor, C-22, Shastri Nagar, Near Central Academy School
Jodhpur, 342001
Rajasthan, India
Tel : 0291-2646000, 2644000, Fax :
CIN - U74899PB1995PLC045956
Email : srl.jodhpur@gmail.com



PATIENT NAME: KUNAL PATHAK 291495	REF. DOCTOR :	SELF
CODE/NAME & ADDRESS : C000138375 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156	ACCESSION NO : <b>0061XC000682</b> PATIENT ID : KUNAM09038861 CLIENT PATIENT ID: ABHA NO :	AGE/SEX :36 Years Male DRAWN : RECEIVED :09/03/2024 10:09:29 REPORTED :09/03/2024 19:37:16
Test Report Status Preliminary	Biological	Reference Interval Units

GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD-<b>Used For</b>:

1. Evaluating the long-term control of blood glucose concentrations in diabetic patients.

2. Diagnosing diabetes.

3. Identifying patients at increased risk for diabetes (prediabetes). The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-And recommends measurements in basic (typically 5-4 times per year lot ype 1 and poorly controlled type 2 diabetic patients, and 2 controlled type 2 diabetic patients) to determine whether a patients metabolic control has remained continuously within the target range.
 AGG (Estimated average glucose) converts percentage HbA1c to md/dl, to compare blood glucose levels.
 eAG gives an evaluation of blood glucose levels for the last couple of months.
 eAG is calculated as eAG (mg/dl) = 28.7 \* HbA1c - 46.7

<b>HbA1c Estimation can get affected due to :</b>1. Shortened Erythrocyte survival : Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss, hemolytic anemia) will falsely lower HbA1c test results.Fructosamine is recommended in these patients which indicates diabetes control over 15 days.
 Vitamin C & E are reported to falsely lower test results.(possibly by inhibiting glycation of hemoglobin.
 Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia,uremia, hyperbilirubinemia, chronic alcoholism,chronic ingestion of salicylates &

opiates addiction are reported to interfere with some assay methods, falsely increasing results. 4. Interference of hemoglobinopathies in HbA1c estimation is seen in

a) Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c.b) Heterozygous state detected (D10 is corrected for HbS & HbC trait.)

c) HbF > 25% on alternate paltform (Boronate affinity chromatography) is recommended for testing of HbA1c. Abnormal Hemoglobin electrophoresis (HPLC method) is recommended for detecting a hemoglobinopathy

Dr. Itisha Dhiman Pathologist



Dr. Tarun Sharma **Consultant Pathologist** 





Page 4 Of 15

View Details





PATIENT NAME: KUNAL PATHAK 291495	<b>REF. DOCTOR :</b> S	SELF
CODE/NAME & ADDRESS : C000138375	ACCESSION NO : 0061XC000682	AGE/SEX : 36 Years Male
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL	PATIENT ID : KUNAM09038861	DRAWN :
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI		RECEIVED : 09/03/2024 10:09:29
NEW DELHI 110030	ABHA NO :	REPORTED :09/03/2024 19:37:16
8800465156		

Test Report Status Preliminary

Results

**Biological Reference Interval** Units

## IMMUNOHAEMATOLOGY

# MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE ABO GROUP & RH TYPE, EDTA WHOLE BLOOD

ABO GROUP	TYPE B
METHOD : FORWARD/REVERSE	
RH TYPE	POSITIVE
METHOD : FORWARD/REVERSE	

<b>Interpretation(s)</b>

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD-Blood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same."

The test is performed by both forward as well as reverse grouping methods.

Dr. Itisha Dhiman Pathologist



Dr. Tarun Sharma Consultant Pathologist





View Report

Page 5 Of 15

View Details





PATIENT NAME: KUNAL PATHAK 291495	<b>REF. DOCTOR :</b> S	SELF
	ACCESSION NO : 0061XC000682	AGE/SEX : 36 Years Male
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST	PATIENT ID : KUNAM09038861	DRAWN :
DELHÍ		RECEIVED : 09/03/2024 10:09:29
	ABHA NO :	REPORTED :09/03/2024 19:37:16
8800465156		

Test Report Status <u>Preliminary</u>

Results

**Biological Reference Interval** Units

	BIOCHEMISTRY		
MEDI WHEEL FULL BODY HEALTH CHEC	CK UP BELOW 40 MALE		)
GLUCOSE FASTING, FLUORIDE PLASMA			
FBS (FASTING BLOOD SUGAR)	115 High	Normal : < 100 Pre-diabetes: 100-125 Diabetes: >/=126	mg/dL
GLUCOSE, POST-PRANDIAL, PLASMA			
PPBS(POST PRANDIAL BLOOD SUGAR) METHOD : SPECTROPHOTOMETRY	94	70 - 140	mg/dL
LIPID PROFILE WITH CALCULATED LDI	L		
CHOLESTEROL, TOTAL	163	< 200 Desirable 200 - 239 Borderline High >/= 240 High	mg/dL
METHOD : SPECTROPHOTOMETRY		. 5	
TRIGLYCERIDES	140	< 150 Normal 150 - 199 Borderline High 200 - 499 High >/=500 Very High	mg/dL
METHOD : SPECTROPHOTOMETRY			
	33 Low	< 40 Low >/=60 High	mg/dL
METHOD : SPECTROPHOTOMETRY CHOLESTEROL LDL	102 High	< 100 Optimal	mg/dL
		100 - 129	
		Near optimal/ above optima	I
		130 - 159	
		Borderline High 160 - 189 High	
		>/= 190 Very High	
NON HDL CHOLESTEROL	130	Desirable: Less than 130 Above Desirable: 130 - 159 Borderline High: 160 - 189 High: 190 - 219	mg/dL
Itisha.			Page 6 Of 15

Dr. Itisha Dhiman Pathologist Dr. Tarun Sharma Consultant Pathologist



View Details





PATIENT NAME : KUNAL PATHAK 291495	<b>REF. DOCTOR :</b>	SELF
CODE/NAME & ADDRESS : C000138375 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL	ACCESSION NO : <b>0061XC000682</b> PATIENT ID : KUNAM09038861	AGE/SEX : 36 Years Male DRAWN :
F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156	CLIENT PATIENT ID: ABHA NO :	RECEIVED :09/03/2024 10:09:29 REPORTED :09/03/2024 19:37:16
Test Report Status <u>Preliminary</u>	Results Biological	Reference Interval Units

VERY LOW DENSITY LIPOPROTEIN	28.0	Very high: > or = 220 = 30.0</th <th>mg/dL</th>	mg/dL
CHOL/HDL RATIO	4.9 High	3.3 - 4.4 Low Risk 4.5 - 7.0 Average Risk 7.1 - 11.0 Moderate Risk > 11.0 High Risk	
LDL/HDL RATIO	3.1 High	0.5 - 3.0 Desirable/Low Risk 3.1 - 6.0 Borderline/Moderat Risk >6.0 High Risk	

# Interpretation(s)

Serum lipid profile is measured for cardiovascular risk prediction. Lipid Association of India recommends LDL-C as primary target and Non HDL-C as co-primary treatment target.

]	Risk Stratification for AS	SCVD (	Atherosclerotic	cardiovascular	disease) by	Lipid Association of India	
	Risk Category						_

		LDL-C (mg/dl)	Non-H	DL (mg/dl)	LDL-C (mg/dl)	Non-HDL (mg/dl)
Risk Group		Treatment Goals			Consider Drug The	erapy
Newer treatment goals and statin initiation thresholds based on the risk categories proposed by LAI in 2020.						
5. Low HDL						
2. Family history of p	remature ASC	CVD		4. High blood	pressure	
1. Age $>$ or $=$ 45 year	s in males and	l > or = 55 years in fema	ales	3. Current Cig	garette smoking or tob	oacco use
		ardiovascular disease)		ctors		
Low Risk	0-1 major ASCVD risk factors					
Moderate Risk	2 major AS	2 major ASCVD risk factors				
		ium - CAC >300 AU. 7	7. Lipopr	otein a >/= 50n	ng/dl 8. Non stenotic	carotid plaque
		CKD stage 3B or 4. 4.				
High Risk	1. Three ma	ajor ASCVD risk factor	s. 2. Dia	betes with 1 m	ajor risk factor or no e	evidence of end organ
	Familial Ho	mozygous Hypercholes	terolemia	a		
Very High Risk	1. Establish	ed ASCVD 2. Diabetes	s with 2 r	najor risk facto	rs or evidence of end	organ damage 3.
	50 mg/dl or	polyvascular disease		-		<i>`</i>
	B. CAD wit	h > 1 feature of Very hi	gh risk g	roup or recurre	nt ACS (within 1 year	r) despite LDL-C < or =
Extreme risk group	A.CAD with > 1 feature of high risk group					
Itisk Category						

Dr. Itisha Dhiman Pathologist



Dr. Tarun Sharma **Consultant Pathologist** 



Page 7 Of 15

View Details





PATIENT NAME: KUNAL PATHAK 291495	REF. DOCTOR : S	SELF
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	PATIENT ID : KUNAM09038861 CLIENT PATIENT ID:	AGE/SEX :36 Years Male DRAWN : RECEIVED :09/03/2024 10:09:29 REPORTED :09/03/2024 19:37:16

#### Test Report Status Prelim

<u>Preliminary</u>

Results

**Biological Reference Interval** Units

Extreme Risk Group Category A	<50 (Optional goal	< 80 (Optional goal	>OR = 50	>OR = 80
	< OR = 30)	< OR = 60)		
Extreme Risk Group Category B	<or 30<="" =="" td=""><td><or 60<="" =="" td=""><td>&gt; 30</td><td>&gt;60</td></or></td></or>	<or 60<="" =="" td=""><td>&gt; 30</td><td>&gt;60</td></or>	> 30	>60
Very High Risk	<50	<80	>OR= 50	>OR= 80
High Risk	<70	<100	>OR= 70	>OR=100
Moderate Risk	<100	<130	>OR=100	>OR=130
Low Risk	<100	<130	>OR=130*	>OR=160

\*After an adequate non-pharmacological intervention for at least 3 months.

**References:** Management of Dyslipidaemia for the Prevention of Stroke: Clinical Practice Recommendations from the Lipid Association of India. Current Vascular Pharmacology, 2022, 20, 134-155.

#### LIVER FUNCTION PROFILE, SERUM BILIRUBIN, TOTAL 0.80 0.2 - 1.0 mg/dL METHOD : SPECTROPHOTOMETRY 0.0 - 0.2mg/dL **BILIRUBIN, DIRECT** 0.10 METHOD : SPECTROPHOTOMETRY BILIRUBIN, INDIRECT 0.70 0.1 - 1.0 mg/dL METHOD : SPECTROPHOTOMETRY 7.7 g/dL TOTAL PROTEIN 6.4 - 8.2 METHOD : SPECTROPHOTOMETRY g/dL ALBUMIN 4.2 3.4 - 5.0 METHOD : SPECTROPHOTOMETRY GLOBULIN 3.5 2.0 - 4.1 g/dL METHOD : CALCULATED PARAMETER ALBUMIN/GLOBULIN RATIO 1.2 1.0 - 2.1 RATIO METHOD : CALCULATED PARAMETER 22 15 - 37 U/L ASPARTATE AMINOTRANSFERASE (AST/SGOT) METHOD : SPECTROPHOTOMETRY U/L ALANINE AMINOTRANSFERASE (ALT/SGPT) 44 < 45.0 METHOD : SPECTROPHOTOMETRY 88 30 - 120 U/L ALKALINE PHOSPHATASE METHOD : SPECTROPHOTOMETRY U/L GAMMA GLUTAMYL TRANSFERASE (GGT) 37 15 - 85 METHOD : SPECTROPHOTOMETRY 85 - 227 U/L LACTATE DEHYDROGENASE 153 METHOD : SPECTROPHOTOMETRY

#### **BLOOD UREA NITROGEN (BUN), SERUM**

Dr. Itisha Dhiman Pathologist



Dr. Tarun Sharma Consultant Pathologist

PERFORMED AT : Agilus Diagnostics Ltd. M/S S.S. Wellness Centre,Ground Floor,C-22,Shastri Nagar,Near Central Academy School Jodhpur, 342001 Rajasthan, India Tel : 0291-2646000, 2644000, Fax : CIN - U74899PB1995PLC045956 Email : srl.jodhpur@gmail.com Page 8 Of 15

View Report



View Details





PATIENT NAME : KUNAL PAT		REF. DOCTOR : SELF	
CODE/NAME & ADDRESS : C0001			:36 Years Male
ARCOFEMI HEALTHCARE LTD (M F-703, LADO SARAI, MEHRAULI		KUNAM09038861 DRAWN	:
DELHI	CLIENT PATIENT IL	1	:09/03/2024 10:09:29
NEW DELHI 110030	ABHA NO :	REPORTED	:09/03/2024 19:37:16
8800465156			
Test Report Status Prelim	<u>ninary</u> Results	Biological Reference	e Interval Units
BLOOD UREA NITROGEN METHOD : SPECTROPHOTOMETRY	10	6 - 20	mg/dL
CREATININE, SERUM			
CREATININE METHOD : SPECTROPHOTOMETRY	1.00	0.90 - 1.30	mg/dL
BUN/CREAT RATIO			
BUN/CREAT RATIO	10.00	5.00 - 15.00	
METHOD : SPECTROPHOTOMETRY			
URIC ACID, SERUM			
URIC ACID	5.8	3.5 - 7.2	mg/dL
METHOD : SPECTROPHOTOMETRY			
TOTAL PROTEIN, SERUM			
TOTAL PROTEIN	7.7	6.4 - 8.2	g/dL
METHOD : SPECTROPHOTOMETRY			
ALBUMIN, SERUM			
ALBUMIN	4.2	3.4 - 5.0	g/dL
METHOD : SPECTROPHOTOMETRY			
GLOBULIN			
GLOBULIN	3.5	2.0 - 4.1	g/dL
METHOD : CALCULATED PARAMETER			
gtisha.	T.		Page 9 Of 15
Dr. Itisha Dhiman	Dr. Tarun Sharma		
Pathologist	Consultant Pathologist		
PERFORMED AT : Agilus Diagnostics Ltd.			View Details View Report



PATIENT NAME: KUNAL PATHAK 291495	REF. DOCTOR	: SELF
CODE/NAME & ADDRESS : C000138375	ACCESSION NO : 0061XC000682	AGE/SEX : 36 Years Male
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST	PATIENT ID : KUNAM09038861	DRAWN :
DELHI	CLIENT PATIENT ID:	RECEIVED : 09/03/2024 10:09:29
NEW DELHI 110030	ABHA NO :	REPORTED :09/03/2024 19:37:16
8800465156		
Test Report Status <u>Preliminary</u>	Results Biologi	cal Reference Interval Units

# ELECTROLYTES (NA/K/CL), SERUM

SODIUM, SERUM	136	136 - 145	mmol/L
METHOD : ION SELECTIVE ELECTRODE TECHNOLOGY			
POTASSIUM, SERUM	4.4	3.50 - 5.10	mmol/L
METHOD : ION SELECTIVE ELECTRODE TECHNOLOGY			
CHLORIDE, SERUM	108 High	98 - 107	mmol/L
METHOD : ION SELECTIVE ELECTRODE TECHNOLOGY			

# Interpretation(s)

Sodium	Potassium	Chloride
Decreased in:CCF, cirrhosis, vomiting, diarrhea, excessive sweating, salt-losing nephropathy, adrenal insufficiency, nephrotic syndrome, water intoxication, SIADH. Drugs: thiazides, diuretics, ACE inhibitors, chlorpropamide, carbamazepine, anti depressants (SSRI), antipsychotics.	Decreased in: Low potassium intake,prolonged vomiting or diarrhea, RTA types I and II, hyperaldosteronism, Cushing's syndrome,osmotic diuresis (e.g., hyperglycemia),alkalosis, familial periodic paralysis,trauma (transient).Drugs: Adrenergic agents, diuretics.	Decreased in: Vomiting, diarrhea, renal failure combined with salt deprivation, over-treatment with diuretics, chronic respiratory acidosis, diabetic ketoacidosis, excessive sweating, SIADH, salt-losing nephropathy, porphyria, expansion of extracellular fluid volume, adrenalinsufficiency, hyperaldosteronism,metabolic alkalosis. Drugs: chronic laxative,corticosteroids, diuretics.
Increased in: Dehydration (excessivesweating, severe vomiting or diarrhea),diabetes mellitus, diabetesinsipidus, hyperaldosteronism, inadequate water intake. Drugs: steroids, licorice,oral contraceptives.	Increased in: Massive hemolysis, severe tissue damage, rhabdomyolysis, acidosis, dehydration,renal failure, Addison's disease, RTA type IV, hyperkalemic familial periodic paralysis. Drugs: potassium salts, potassium- sparing diuretics,NSAIDs, beta-blockers, ACE inhibitors, high- dose trimethoprim-sulfamethoxazole.	Increased in: Renal failure, nephrotic syndrome, RTA, dehydration, overtreatment with saline, hyperparathyroidism, diabetes insipidus, metabolic acidosis from diarrhea (Loss of HCO3-), respiratory alkalosis, hyperadrenocorticism. Drugs: acetazolamide, androgens, hydrochlorothiazide, salicylates.
Interferences: Severe lipemia or hyperproteinemi, if sodium analysis involves a dilution step can cause spurious results. The serum sodium falls about 1.6 mEq/L for each 100 mg/dL increase in blood glucose.	Interferences: Hemolysis of sample, delayed separation of serum, prolonged fist clenching during blood drawing, and prolonged tourniquet placement. Very high WBC/PLT counts may cause spurious. Plasma potassium levels are normal.	Interferences:Test is helpful in assessing normal and increased anion gap metabolic acidosis and in distinguishing hypercalcemia due to hyperparathyroidism (high serum chloride) from that due to malignancy (Normal serum chloride)

gtisha

Dr. Itisha Dhiman Pathologist



Dr. Tarun Sharma Consultant Pathologist





View Report

Page 10 Of 15

View Details





PATIENT NAME: KUNAL PATHAK 291495	<b>REF. DOCTOR :</b>	SELF
CODE/NAME & ADDRESS : C000138375 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156	ACCESSION NO : <b>0061XC000682</b> PATIENT ID : KUNAM09038861 CLIENT PATIENT ID: ABHA NO :	AGE/SEX :36 Years Male DRAWN : RECEIVED :09/03/2024 10:09:29 REPORTED :09/03/2024 19:37:16
Test Report Status Preliminary	Results Biological	Reference Interval Units

<b>Interpretation(s)</b> GLUCOSE FASTING,FLUORIDE PLASMA-<b>TEST DESCRIPTION</b>

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and sothat no glucose is excreted in the urine

<b>Increased in</b>:Diabetes mellitus, Cushing's syndrome (10 – 15%), chronic pancreatitis (30%). Drugs:corticosteroids, phenytoin, estrogen, thiazides. (adrenocortical,stomach,fibrosarcoma),infant of a diabetic mother,enzyme deficiency diseases(e.g.galactosemia),Drugs-insulin,ethanol,propranolol sulfonylureas, tolbutamide, and other oral hypoglycemic agents.

<b>NOTE:</b> While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values), there is wide fluctuation within individuals. Thus, glycosylated hemoglobin(HbA1c) levels are favored to monitor glycemic control.

Michine Individuals. Inds, giycosylated nemoglobin(IDATC) levels are favored to monitor glycemic control. High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc. GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc. LIVER FUNCTION PROFILE, SERUM-the planetary hypoglycemic and the bila and in a burglid una surdict of consumed have a state in a profession of the planetary hypoglycemic and the bila and in a burglid una surdiction of the planetary hypoglycemic and the bila and in a burglid una surdiction of the planetary hypoglycemic and the bila and in a burglid una surdiction of the planetary hypoglycemic and the bila and in a burglid una surdiction of the planetary hypoglycemic and the bila and in a burglid una surdiction of the planetary hypoglycemic and the bila and in a burglid una surdiction of the planetary hypoglycemic and the bila and in a burglid una surdiction of the planetary hypoglycemic and the bila and the bila and the bila and the planetary hypoglycemic and burglid una surdiction of the bila and the bila and the planetary hypoglycemic and the bila and the bila and the bila and the planetary hypoglycemic and the bila and the planetary hypoglycemic and the bila and the bila

<b>Bilirubin</b> is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give yellow discoloration in jaundice. <b>Elevated levels</b> results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin when there is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors & Scarring of the bile ducts. Increased unconjugated (indirect) bilirubin may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin.

<b>AST</b> is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver, liver cancer, kidney failure, hemolytic anemia, pancreatitis, hemochromatosis. AST levels may also increase after a heart attack or strenuous activity. ALT test measures the amount of this enzyme in the blood.ALT is found mainly in the liver, but also in smaller amounts in the kidneys, heart, muscles, and pancreas. It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health.AST levels increase during acute hepatitis, sometimes due to a viral infection, ischemia to the liver, chronic hepatitis, obstruction of bile ducts, cirrhosis.

<b>ALP</b> is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction, Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Pagets disease, Rickets, Sarcoidosis etc. Lower-than-normal

ALP levels seen in Hypophosphatasia, Malnutrition, Protein deficiency, Wilsons disease. <br/>
<

d>Total Protein
also known as total protein; is a biochemical test for measuring the total amount of protein in serum.Protein in the plasma is made up of albumin and globulin.Higher-than-normal levels may be due to:Chronic inflammation or infection,including HIV and hepatitis B or C,Multiple myeloma,Waldenstroms disease.Lower-than-normal levels may be due to: Agammaglobulinemia,Bleeding (hemorrhage),Burns,Glomerulonephritis,Liver disease,

Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc. <b>Albumin</b> is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by:Liver disease like cirrhosis of the liver, nephrotic syndrome,protein-losing enteropathy,Burns,hemodilution,increased vascular permeability or decreased lymphatic clearance,malnutrition and wasting etc

BLOOD UREA NITROGEN (BUN), SERUM-<br/>blood a per inclusion of the second per construction and interview of the second per construction and the seco

CREATININE, SERUM-<b>Higher than normal level may be due to:</b>

Blockage in the urinary tract, Kidney problems, such as kidney damage or failure, infection, or reduced blood flow, Loss of body fluid (dehydration), Muscle problems, such as breakdown of muscle fibers, Problems during pregnancy, such as seizures (eclampsia)), or high blood pressure caused by pregnancy (preeclampsia) <b>Lower than normal level may be due to:</b>• Myasthenia Gravis, Muscuophy URIC ACID, SERUM-<b>Causes of Increased levels:</b>-Dietary(High Protein Intake,Prolonged Fasting,Rapid weight loss),Gout,Lesch nyhan syndrome,Type 2

DM,Metabolic syndrome Causes of decreased levels
Low Zinc intake,OCP,Multiple Sclerosis
TOTAL PROTEIN, SERUM-is a biochemical test for measuring the total amount of protein in serum.Protein in the plasma is made up of albumin and globulin.

<b>>Higher-than-normal levels may be due to:</b> Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms disease <b>Lower-than-normal levels may be due to:</b> Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc.

ALBUMIN, SERUM-Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. <b>Low blood albumin levels (hypoalbuminemia) can be caused by:</b> Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance,malnutrition and wasting etc.

Dr. Itisha Dhiman Pathologist



Dr. Tarun Sharma **Consultant Pathologist** 





View Report

Page 11 Of 15

View Details





PATIENT NAME: KUNAL PATHAK 291495	REF. DOCTOR :	SELF
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	ACCESSION NO : <b>0061XC000682</b> PATIENT ID : KUNAM09038861 CLIENT PATIENT ID: ABHA NO :	AGE/SEX :36 Years Male DRAWN : RECEIVED :09/03/2024 10:09:29 REPORTED :09/03/2024 19:37:16
Test Report Status <u>Preliminary</u>	Results Biological	Reference Interval Units

CLINICAL PATH - URINALYSIS			
MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE			
PHYSICAL EXAMINATION, URINE			
COLOR	PALE YELLOW		
APPEARANCE	CLEAR		
CHEMICAL EXAMINATION, URINE			
PH	6.0	4.7 - 7.5	
SPECIFIC GRAVITY	1.020	1.003 - 1.035	
PROTEIN	NOT DETECTED	NOT DETECTED	
GLUCOSE	NOT DETECTED	NOT DETECTED	
KETONES	NOT DETECTED	NOT DETECTED	
BLOOD	NOT DETECTED	NOT DETECTED	
BILIRUBIN	NOT DETECTED	NOT DETECTED	
UROBILINOGEN	NORMAL	NORMAL	
NITRITE	NOT DETECTED	NOT DETECTED	
LEUKOCYTE ESTERASE	NOT DETECTED	NOT DETECTED	
MICROSCOPIC EXAMINATION, URINE			
RED BLOOD CELLS	NOT DETECTED	NOT DETECTED	/HPF
PUS CELL (WBC'S)	3-5	0-5	/HPF
EPITHELIAL CELLS	2-3	0-5	/HPF
CASTS	NOT DETECTED		
CRYSTALS	NOT DETECTED		
BACTERIA	DETECTED	NOT DETECTED	
	(OCCASIONAL)		

METHOD : MICROSCOPIC EXAMINATION

gtisha

Dr. Itisha Dhiman Pathologist



Dr. Tarun Sharma Consultant Pathologist

PERFORMED AT : Agilus Diagnostics Ltd. M/S S.S. Wellness Centre,Ground Floor,C-22,Shastri Nagar,Near Central Academy School Jodhpur, 342001 Rajasthan, India Tel : 0291-2646000, 2644000, Fax : CIN - U74899PB1995PLC045956 Email : srl.jodhpur@gmail.com Page 12 Of 15





View Details





PATIENT NAME: KUNAL PATHAK 291495	REF. DOCTOR :	SELF
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	ACCESSION NO: <b>0061XC000682</b> PATIENT ID : KUNAM09038861 CLIENT PATIENT ID: ABHA NO :	AGE/SEX :36 Years Male DRAWN : RECEIVED :09/03/2024 10:09:29 REPORTED :09/03/2024 19:37:16
Test Report Status <u>Preliminary</u>	Results Biological	Reference Interval Units

### Interpretation(s)

The following table describes the probable conditions, in which the analytes are present in urine

Presence of	Conditions
Proteins	Inflammation or immune illnesses
Pus (White Blood Cells)	Urinary tract infection, urinary tract or kidney stone, tumors or any kind of kidney impairment
Glucose	Diabetes or kidney disease
Ketones	Diabetic ketoacidosis (DKA), starvation or thirst
Urobilinogen	Liver disease such as hepatitis or cirrhosis
Blood	Renal or genital disorders/trauma
Bilirubin	Liver disease
Erythrocytes	Urological diseases (e.g. kidney and bladder cancer, urolithiasis), urinary tract infection and glomerular diseases
Leukocytes	Urinary tract infection, glomerulonephritis, interstitial nephritis either acute or chronic, polycystic kidney disease, urolithiasis, contamination by genital secretions
Epithelial cells	Urolithiasis, bladder carcinoma or hydronephrosis, ureteric stents or bladder catheters for prolonged periods of time
Granular Casts	Low intratubular pH, high urine osmolality and sodium concentration, interaction with Bence-Jones protein
Hyaline casts	Physical stress, fever, dehydration, acute congestive heart failure, renal diseases
Calcium oxalate	Metabolic stone disease, primary or secondary hyperoxaluria, intravenous infusion of large doses of vitamin C, the use of vasodilator naftidrofuryl oxalate or the gastrointestinal lipase inhibitor orlistat, ingestion of ethylene glycol or of star fruit (Averrhoa carambola) or its juice
Uric acid	arthritis
Bacteria	Urinary infectionwhen present in significant numbers & with pus cells.
Trichomonas vaginalis	Vaginitis, cervicitis or salpingitis

gtis

Dr. Itisha Dhiman Pathologist



Dr. Tarun Sharma Consultant Pathologist





View Report

Page 13 Of 15

View Details





PATIENT NAME: KUNAL PATHAK 291495	REF. DOCTOR	: SELF
CODE/NAME & ADDRESS : C000138375 ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI NEW DELHI 110030 8800465156	ACCESSION NO : <b>0061XC000682</b> PATIENT ID : KUNAM09038861 CLIENT PATIENT ID: ABHA NO :	AGE/SEX :36 Years Male DRAWN : RECEIVED :09/03/2024 10:09:29 REPORTED :09/03/2024 19:37:16
Test Report Status <u>Preliminary</u>	Results Biologi	cal Reference Interval Units

CLINI	CAL PATH - STOOL ANALYSIS	
MEDI WHEEL FULL BODY HEALTH CHECK UP	BELOWERDIMATE	
PHYSICAL EXAMINATION, STOOL	RESULT PENDING	
CHEMICAL EXAMINATION, STOOL	RESULT PENDING	
MICROSCOPIC EXAMINATION, STOOL	RESULT PENDING	

Page 14 Of 15





View Details





.....

PATIENT NAME: KUNAL PATHAK 291495	REF. DOCTOR : S	SELF
ARCOFEMI HEALTHCARE LTD (MEDIWHEEL F-703, LADO SARAI, MEHRAULISOUTH WEST DELHI	PATIENT ID : KUNAM09038861 CLIENT PATIENT ID:	AGE/SEX       :36 Years       Male         DRAWN       :         RECEIVED       :09/03/2024       10:09:29         REPORTED       :09/03/2024       19:37:16
Test Report Status Preliminary	Results Biological	Reference Interval Units

.....

**Biological Reference Interval** Units

#### **SPECIALISED CHEMISTRY - HORMONE**

MEDI WHEEL FULL BODY HEALTH CHECK UP BELOW 40 MALE	

THYROID PANEL, SERUM			
ТЗ	127.60	80.0 - 200.0	ng/dL
T4	7.32	5.10 - 14.10	µg/dL
TSH (ULTRASENSITIVE)	3.750	0.270 - 4.200	µIU/mL

\*\*End Of Report\*\* Please visit www.agilusdiagnostics.com for related Test Information for this accession

CONDITIONS OF LABORATO	RY TESTING & REPORTING
<ol> <li>It is presumed that the test sample belongs to the patient named or identified in the test requisition form.</li> <li>All tests are performed and reported as per the turnaround time stated in the AGILUS Directory of Services.</li> <li>Result delays could occur due to unforeseen circumstances such as non-availability of kits / equipment breakdown / natural calamities / technical downtime or any other unforeseen event.</li> <li>A requested test might not be performed if:         <ol> <li>Specimen quality is unsatisfactory</li> <li>Incorrect specimen type</li> <li>Discrepancy between identification on specimen container label and test requisition form</li> </ol> </li> </ol>	<ol> <li>AGILUS Diagnostics confirms that all tests have been performed or assayed with highest quality standards, clinical safety &amp; technical integrity.</li> <li>Laboratory results should not be interpreted in isolation; it must be correlated with clinical information and be interpreted by registered medical practitioners only to determine final diagnosis.</li> <li>Test results may vary based on time of collection, physiological condition of the patient, current medication or nutritional and dietary changes. Please consult your doctor or call us for any clarification.</li> <li>Test results cannot be used for Medico legal purposes.</li> <li>In case of queries please call customer care (91115 91115) within 48 hours of the report.</li> </ol>
	Agilus Diagnostics Ltd Fortis Hospital, Sector 62, Phase VIII, Mohali 160062

Dr. Itisha Dhiman Pathologist



Dr. Tarun Sharma **Consultant Pathologist** 

Page 15 Of 15

View Report

View Details



8